Edward White
Stock Analyst at HC Wainwright & Co.
(2.93)
# 1,267
Out of 4,412 analysts
230
Total ratings
31.92%
Success rate
1.82%
Average return
Main Sectors:
27 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Reiterates: Buy | $41 | $21.06 | +94.68% | 17 | Apr 26, 2024 | |
| TGTX TG Therapeutics | Reiterates: Buy | $45 | $13.47 | +234.08% | 21 | Apr 18, 2024 | |
| SABS SAB Biotherapeutics | Reiterates: Buy | $6 | $4.25 | +41.18% | 11 | Apr 16, 2024 | |
| CGEM Cullinan Oncology | Maintains: Buy | $34 → $29 | $25.30 | +14.62% | 15 | Apr 16, 2024 | |
| TCON TRACON Pharmaceuticals | Maintains: Buy | $120 → $60 | $1.81 | +3,214.92% | 11 | Apr 3, 2024 | |
| SXTP 60 Degrees Pharmaceuticals | Reiterates: Neutral | n/a | $0.24 | - | 2 | Apr 3, 2024 | |
| ACET Adicet Bio | Maintains: Buy | $10 | $1.68 | +495.24% | 9 | Apr 2, 2024 | |
| GLYC GlycoMimetics | Maintains: Buy | $8 | $1.64 | +387.80% | 8 | Mar 27, 2024 | |
| NYXH Nyxoah | Reiterates: Buy | n/a | $10.62 | - | 7 | Mar 25, 2024 | |
| BOLT Bolt Biotherapeutics | Maintains: Buy | $8 | $1.11 | +620.72% | 8 | Mar 22, 2024 | |
| IFRX InflaRx | Reiterates: Buy | $8 | $1.33 | +501.50% | 13 | Mar 22, 2024 | |
| VALN Valneva SE | Reiterates: Buy | $26 | $7.64 | +240.32% | 17 | Mar 21, 2024 | |
| LUMO Lumos Pharma | Reiterates: Buy | $28 | $2.77 | +910.83% | 11 | Mar 20, 2024 | |
| INZY Inozyme Pharma | Maintains: Buy | $16 | $4.44 | +260.36% | 6 | Mar 13, 2024 | |
| IKT Inhibikase Therapeutics | Reiterates: Buy | $27 | $1.71 | +1,478.95% | 6 | Mar 7, 2024 | |
| PBYI Puma Biotechnology | Maintains: Buy | $8 → $7 | $5.02 | +39.44% | 9 | Mar 1, 2024 | |
| CMRX Chimerix | Reiterates: Buy | $11 | $0.90 | +1,122.36% | 9 | Mar 1, 2024 | |
| KPTI Karyopharm Therapeutics | Maintains: Buy | $10 → $8 | $1.06 | +654.72% | 13 | Mar 1, 2024 | |
| CRIS Curis | Maintains: Buy | $51 → $26 | $14.47 | +79.68% | 8 | Feb 9, 2024 | |
| SNSE Sensei Biotherapeutics | Initiates: Buy | $4 | $1.02 | +292.16% | 1 | Dec 4, 2023 | |
| DVAX Dynavax Technologies | Maintains: Buy | $27 → $28 | $11.21 | +149.78% | 9 | Nov 3, 2023 | |
| GTHX G1 Therapeutics | Reiterates: Buy | $11 | $3.99 | +175.69% | 9 | Aug 3, 2023 | |
| ALRN Aileron Therapeutics | Maintains: Buy | $40 → $20 | $5.00 | +300.00% | 2 | Jun 30, 2022 | |
| PMCB PharmaCyte Biotech | Initiates: Neutral | n/a | $2.11 | - | 1 | Nov 8, 2021 | |
| MRSN Mersana Therapeutics | Initiates: Buy | n/a | $2.94 | - | 1 | Aug 30, 2021 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | n/a | $39.94 | - | 4 | Aug 11, 2021 | |
| FATE Fate Therapeutics | Downgrades: Neutral | n/a | $3.80 | - | 2 | Mar 6, 2018 |
Syndax Pharmaceuticals
Apr 26, 2024
Reiterates: Buy
Price Target: $41
Current: $21.06
Upside: +94.68%
TG Therapeutics
Apr 18, 2024
Reiterates: Buy
Price Target: $45
Current: $13.47
Upside: +234.08%
SAB Biotherapeutics
Apr 16, 2024
Reiterates: Buy
Price Target: $6
Current: $4.25
Upside: +41.18%
Cullinan Oncology
Apr 16, 2024
Maintains: Buy
Price Target: $34 → $29
Current: $25.30
Upside: +14.62%
TRACON Pharmaceuticals
Apr 3, 2024
Maintains: Buy
Price Target: $120 → $60
Current: $1.81
Upside: +3,214.92%
60 Degrees Pharmaceuticals
Apr 3, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.24
Upside: -
Adicet Bio
Apr 2, 2024
Maintains: Buy
Price Target: $10
Current: $1.68
Upside: +495.24%
GlycoMimetics
Mar 27, 2024
Maintains: Buy
Price Target: $8
Current: $1.64
Upside: +387.80%
Nyxoah
Mar 25, 2024
Reiterates: Buy
Price Target: n/a
Current: $10.62
Upside: -
Bolt Biotherapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $8
Current: $1.11
Upside: +620.72%
InflaRx
Mar 22, 2024
Reiterates: Buy
Price Target: $8
Current: $1.33
Upside: +501.50%
Valneva SE
Mar 21, 2024
Reiterates: Buy
Price Target: $26
Current: $7.64
Upside: +240.32%
Lumos Pharma
Mar 20, 2024
Reiterates: Buy
Price Target: $28
Current: $2.77
Upside: +910.83%
Inozyme Pharma
Mar 13, 2024
Maintains: Buy
Price Target: $16
Current: $4.44
Upside: +260.36%
Inhibikase Therapeutics
Mar 7, 2024
Reiterates: Buy
Price Target: $27
Current: $1.71
Upside: +1,478.95%
Puma Biotechnology
Mar 1, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $5.02
Upside: +39.44%
Chimerix
Mar 1, 2024
Reiterates: Buy
Price Target: $11
Current: $0.90
Upside: +1,122.36%
Karyopharm Therapeutics
Mar 1, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $1.06
Upside: +654.72%
Curis
Feb 9, 2024
Maintains: Buy
Price Target: $51 → $26
Current: $14.47
Upside: +79.68%
Sensei Biotherapeutics
Dec 4, 2023
Initiates: Buy
Price Target: $4
Current: $1.02
Upside: +292.16%
Dynavax Technologies
Nov 3, 2023
Maintains: Buy
Price Target: $27 → $28
Current: $11.21
Upside: +149.78%
G1 Therapeutics
Aug 3, 2023
Reiterates: Buy
Price Target: $11
Current: $3.99
Upside: +175.69%
Aileron Therapeutics
Jun 30, 2022
Maintains: Buy
Price Target: $40 → $20
Current: $5.00
Upside: +300.00%
PharmaCyte Biotech
Nov 8, 2021
Initiates: Neutral
Price Target: n/a
Current: $2.11
Upside: -
Mersana Therapeutics
Aug 30, 2021
Initiates: Buy
Price Target: n/a
Current: $2.94
Upside: -
IDEAYA Biosciences
Aug 11, 2021
Maintains: Buy
Price Target: n/a
Current: $39.94
Upside: -
Fate Therapeutics
Mar 6, 2018
Downgrades: Neutral
Price Target: n/a
Current: $3.80
Upside: -